We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elanco Animal Health (ELAN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
The upcoming report from Elanco Animal Health Incorporated (ELAN - Free Report) is expected to reveal quarterly earnings of $0.12 per share, indicating a decline of 33.3% compared to the year-ago period. Analysts forecast revenues of $1.03 billion, representing a decrease of 3.2% year over year.
Over the last 30 days, there has been an upward revision of 1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Elanco Animal Health metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenue- Total Pet Health' will likely reach $490.64 million. The estimate indicates a change of -0.9% from the prior-year quarter.
The consensus estimate for 'Revenue- Total Contract Manufacturing' stands at $10.47 million. The estimate indicates a change of -12.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Total Farm Animal' of $533.43 million. The estimate indicates a change of -4.9% from the prior-year quarter.
Over the past month, Elanco Animal Health shares have recorded returns of -14.1% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), ELAN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Elanco Animal Health (ELAN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
The upcoming report from Elanco Animal Health Incorporated (ELAN - Free Report) is expected to reveal quarterly earnings of $0.12 per share, indicating a decline of 33.3% compared to the year-ago period. Analysts forecast revenues of $1.03 billion, representing a decrease of 3.2% year over year.
Over the last 30 days, there has been an upward revision of 1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Elanco Animal Health metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenue- Total Pet Health' will likely reach $490.64 million. The estimate indicates a change of -0.9% from the prior-year quarter.
The consensus estimate for 'Revenue- Total Contract Manufacturing' stands at $10.47 million. The estimate indicates a change of -12.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Total Farm Animal' of $533.43 million. The estimate indicates a change of -4.9% from the prior-year quarter.
View all Key Company Metrics for Elanco Animal Health here>>>
Over the past month, Elanco Animal Health shares have recorded returns of -14.1% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), ELAN will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>